No label defined (Q33669)

From lgbtDB
Revision as of 19:49, 19 November 2024 by Superraptor (talk | contribs) (‎Created a new Item)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
No description defined
  • The Use of Injectable Estradiol in Transgender and Gender Diverse Adults: A Scoping Review of Dose and Serum Estradiol Levels.
Language Label Description Also known as
English
No label defined
No description defined
  • The Use of Injectable Estradiol in Transgender and Gender Diverse Adults: A Scoping Review of Dose and Serum Estradiol Levels.

Statements

title
The Use of Injectable Estradiol in Transgender and Gender Diverse Adults: A Scoping Review of Dose and Serum Estradiol Levels. (English)
1 reference
stated in
PubMed
abstract
Feminizing gender-affirming hormone therapy is the mainstay of treatment for many transgender and gender diverse people. (English)
source label
OBJECTIVE (English)
subsection NLM category
objective section
series ordinal
1
copyright statement
Copyright © 2024 AACE. All rights reserved. (English)
date copyrighted
2024
rights holder
American Association of Clinical Endocrinology
1 reference
stated in
PubMed
Injectable estradiol preparations are recommended by the World Professional Association for Transgender Health Standards of Care 8 and the Endocrine Society guidelines. (English)
source label
OBJECTIVE (English)
subsection NLM category
objective section
series ordinal
2
copyright statement
Copyright © 2024 AACE. All rights reserved. (English)
date copyrighted
2024
rights holder
American Association of Clinical Endocrinology
1 reference
stated in
PubMed
Many patients prefer this route of administration, but few studies have rigorously assessed optimal dosing or route. (English)
source label
OBJECTIVE (English)
subsection NLM category
objective section
series ordinal
3
copyright statement
Copyright © 2024 AACE. All rights reserved. (English)
date copyrighted
2024
rights holder
American Association of Clinical Endocrinology
1 reference
stated in
PubMed
We performed a scoping review of the available data on estradiol levels achieved with various dosages of estradiol injections in transgender and gender diverse adults on feminizing gender-affirming hormone therapy. (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
4
copyright statement
Copyright © 2024 AACE. All rights reserved. (English)
date copyrighted
2024
rights holder
American Association of Clinical Endocrinology
1 reference
stated in
PubMed
We also report on testosterone suppression, route (ie, subcutaneous vs intramuscular), and type of injectable estradiol ester as well as timing of blood draw relative to the most recent dose, where available. (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
5
copyright statement
Copyright © 2024 AACE. All rights reserved. (English)
date copyrighted
2024
rights holder
American Association of Clinical Endocrinology
1 reference
stated in
PubMed
The data we reviewed suggest that the current guidelines, which recommend starting doses 2 to 10 mg weekly or 5 to 30 mg every 2 weeks of estradiol cypionate or valerate, are too high and likely lead to patients having supraphysiologic levels across much of their injection cycle. (English)
source label
RESULTS (English)
subsection NLM category
results section
series ordinal
6
copyright statement
Copyright © 2024 AACE. All rights reserved. (English)
date copyrighted
2024
rights holder
American Association of Clinical Endocrinology
1 reference
stated in
PubMed
The optimal starting dose for injectable estradiol remains unclear and whether it should differ for cypionate and valerate. (English)
source label
CONCLUSIONS (English)
subsection NLM category
conclusion section
series ordinal
7
copyright statement
Copyright © 2024 AACE. All rights reserved. (English)
date copyrighted
2024
rights holder
American Association of Clinical Endocrinology
1 reference
stated in
PubMed
Based on the data available, we suggest that clinicians start injectable estradiol cypionate or valerate via subcutaneous or intramuscular injections at a dose ≤5 mg weekly and then titrate accordingly to keep levels within guideline-recommended range. (English)
source label
CONCLUSIONS (English)
subsection NLM category
conclusion section
series ordinal
8
copyright statement
Copyright © 2024 AACE. All rights reserved. (English)
date copyrighted
2024
rights holder
American Association of Clinical Endocrinology
1 reference
stated in
PubMed
Future studies should assess timing of injections and subsequent levels more precisely across the injection cycle and between esters. (English)
source label
CONCLUSIONS (English)
subsection NLM category
conclusion section
series ordinal
9
copyright statement
Copyright © 2024 AACE. All rights reserved. (English)
date copyrighted
2024
rights holder
American Association of Clinical Endocrinology
1 reference
stated in
PubMed
date published
September 2024
1 reference
stated in
PubMed
date issued
September 2024
1 reference
stated in
PubMed
author
volume
30
1 reference
stated in
PubMed
issue
9
1 reference
stated in
PubMed
page(s)
870-878
1 reference
stated in
PubMed
page start
870
1 reference
stated in
PubMed
page end
878
1 reference
stated in
PubMed
publisher item identifier
S1530-891X(24)00530-5
1 reference
stated in
PubMed
conflict-of-interest statement
Disclosure The authors have no multiplicity of interest to disclose. (English)
series ordinal
1
1 reference
stated in
PubMed
 
Retrieved from "https://lgbtdb.wikibase.cloud/w/index.php?title=Item:Q33669&oldid=193960"